TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nyxoah ( (NYXH) ) has issued an update.
On November 13, 2025, Nyxoah SA entered into a securities purchase agreement with certain investors, including institutional investors, to issue and sell 1,215,964 ordinary shares at $4.6304 per share in a registered direct offering. This transaction is expected to generate approximately $5.6 million in gross proceeds for the company, which could potentially enhance its financial position and support its ongoing operations and strategic initiatives in the medical technology sector.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR13.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a Belgian company operating in the medical technology industry. The company specializes in developing innovative solutions for the treatment of sleep apnea, focusing on neurostimulation devices that aim to improve the quality of life for patients with this condition.
Average Trading Volume: 85,653
Current Market Cap: €181.5M
For an in-depth examination of NYXH stock, go to TipRanks’ Overview page.